← Leaderboards
Lijun Sun
Beth Israel Deaconess Medical Center
$1,635,595
Attributed
$3,271,189
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $705.9K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,271,189 · 2
By mechanism
R01$2,795,439 · 1
R21$475,750 · 1
Top collaborators
- Elliot Chaikof4 shared
- Leena Pradhan-Nabzdyk2 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- George C Tsokos$40,494,511
- Sheila M Thomas$4,476,387
- Kara Gross Margolis$5,050,186
- Raghu Kalluri$29,360,132
- Frank W Logerfo$21,342,043
Others in their field
Top investigators on “Production”
- Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
- Bambra Strokes · Ppd Development Lp$526,656,217
- Richard A Gibbs · Baylor College Of Medicine$521,766,399
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970
Research focus
ProductionPathway InteractionsStructureCostPreventionLigandsPharmaceutical PreparationsScaffoldTissuesT-LymphocyteSignal TransductionProtocols DocumentationDrug DesignAntibodiesDysbiosisDoseDisorder RiskDrug CandidateEffectivenessBiodistributionAryl Hydrocarbon Receptor LigandAgonistAdultAryl Hydrocarbon Receptor
Grant awards (6)
Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD$705,947
R01 · FY2025 · DK
Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD$677,710
R01 · FY2024 · DK
Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD$705,947
R01 · FY2023 · DK
Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD$705,835
R01 · FY2022 · DK
Development of Small Molecule Inhibitors of IL-18 to Prevent Intimal Hyperplasia$216,250
R21 · FY2017 · HL
Development of Small Molecule Inhibitors of IL-18 to Prevent Intimal Hyperplasia$259,500
R21 · FY2016 · HL